Cyclo Therapeutics (Cyclo Therapeutics) Net Margin %

: -1,814.15% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Cyclo Therapeutics's Net Income for the three months ended in Dec. 2023 was $-5.64 Mil. Cyclo Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.31 Mil. Therefore, Cyclo Therapeutics's net margin for the quarter that ended in Dec. 2023 was -1,814.15%.

The historical rank and industry rank for Cyclo Therapeutics's Net Margin % or its related term are showing as below:

CYTHW' s Net Margin % Range Over the Past 10 Years
Min: -1865.67 Med: -584.47 Max: -37.84
Current: -1865.67

CYTHW's Net Margin % is ranked worse than
96.47% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 3.765 vs CYTHW: -1865.67

Cyclo Therapeutics Net Margin % Historical Data

The historical data trend for Cyclo Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

-748.06

-990.25

-900.82

-1,122.89

-1,864.03

Cyclo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-2,663.10	-3,294.08	-3,962.39	-963.84	-1,814.15

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclo Therapeutics Net Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Net Margin % falls into.

Cyclo Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cyclo Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-20.057	/	1.076
	=	-1,864.03 %

Cyclo Therapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-5.642	/	0.311
	=	-1,814.15 %

Cyclo Therapeutics (NAS:CYTHW) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Cyclo Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTHW) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

CYTH:USA

Address

6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653

Website

https://www.cyclodex.com

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.